Analysis of Transcriptome Alterations in Parkinson’s Disease
暂无分享,去创建一个
[1] E. Sinforiani,et al. Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease , 2011, Neurobiology of Aging.
[2] S. Illarioshkin,et al. [Expression of GSK3B gene in peripheral blood in patient with Parkinson's disease]. , 2011, Molekuliarnaia biologiia.
[3] C. Zechner,et al. Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. , 2010, Cell metabolism.
[4] P. Riederer,et al. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease , 2010, Journal of Neural Transmission.
[5] Manuel B. Graeber,et al. PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.
[6] B. de Strooper,et al. Dysregulated microRNAs in neurodegenerative disorders. , 2010, Seminars in cell & developmental biology.
[7] Shoji Nakamura,et al. Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease , 2010, Brain Research.
[8] V. Álvarez,et al. FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients , 2010, Neuroscience Letters.
[9] Julie A Saugstad,et al. MicroRNAs as Effectors of Brain Function with Roles in Ischemia and Injury, Neuroprotection, and Neurodegeneration , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] A. Gulino,et al. MicroRNAs as biomarkers for CNS cancer and other disorders , 2010, Brain Research.
[11] S. Limborska,et al. Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease , 2010, Neuroscience Letters.
[12] E. Eriksson,et al. PITX3 polymorphism is associated with early onset Parkinson's disease , 2010, Neurobiology of Aging.
[13] Epaminondas Doxakis,et al. Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153 , 2010, The Journal of Biological Chemistry.
[14] Ming Yi,et al. Evidence for Gender-Specific Transcriptional Profiles of Nigral Dopamine Neurons in Parkinson Disease , 2010, PloS one.
[15] Desmond J. Smith. Mitochondrial dysfunction in mouse models of Parkinson’s disease revealed by transcriptomics and proteomics , 2009, Journal of bioenergetics and biomembranes.
[16] S. Mandel,et al. Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A. , 2009, Parkinsonism & related disorders.
[17] V. Scaria,et al. MicroRNAs: novel therapeutic targets in neurodegenerative diseases. , 2009, Drug discovery today.
[18] I. McKeith,et al. Single‐cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene , 2009, Annals of neurology.
[19] N. Arora,et al. Interaction Map and Selection of microRNA Targets in Parkinson's Disease-Related Genes , 2009, Journal of biomedicine & biotechnology.
[20] C. Barbato,et al. Searching for MIND: MicroRNAs in Neurodegenerative Diseases , 2009, Journal of biomedicine & biotechnology.
[21] J. Im,et al. Repression of α-synuclein expression and toxicity by microRNA-7 , 2009, Proceedings of the National Academy of Sciences.
[22] M. Horan. Application of serial analysis of gene expression to the study of human genetic disease , 2009, Human Genetics.
[23] F. Benes,et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. , 2009, Brain : a journal of neurology.
[24] T. Illig,et al. The transcription factor PITX3 is associated with sporadic Parkinson's disease , 2009, Neurobiology of Aging.
[25] F. Mastaglia,et al. Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? , 2009, Movement disorders : official journal of the Movement Disorder Society.
[26] M. Wood,et al. Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. , 2009, Human molecular genetics.
[27] Lan Jin,et al. Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. , 2009, Nature structural & molecular biology.
[28] M. Onofrj,et al. Peripheral cytokines profile in Parkinson’s disease , 2009, Brain, Behavior, and Immunity.
[29] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[30] C. Kruse,et al. Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death , 2009, Brain pathology.
[31] Yi Wen Kong,et al. How do microRNAs regulate gene expression? , 2008, Biochemical Society transactions.
[32] Praveen Sethupathy,et al. MicroRNA target site polymorphisms and human disease. , 2008, Trends in genetics : TIG.
[33] Chunxu Qu,et al. Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum , 2008, Neuroscience.
[34] G. Schratt,et al. MicroRNA function in neuronal development, plasticity and disease. , 2008, Biochimica et biophysica acta.
[35] Alan Mackay-Sim,et al. Fibroblast and Lymphoblast Gene Expression Profiles in Schizophrenia: Are Non-Neural Cells Informative? , 2008, PloS one.
[36] S. Cohen,et al. microRNAs in neurodegeneration , 2008, Current Opinion in Neurobiology.
[37] Michael T. McManus,et al. Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration , 2008, Proceedings of the National Academy of Sciences.
[38] B. Hyman,et al. Transcriptional dysregulation in a transgenic model of Parkinson disease , 2008, Neurobiology of Disease.
[39] Gaofeng Wang,et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.
[40] W. Filipowicz,et al. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.
[41] A. Schier,et al. Members of the miRNA-200 Family Regulate Olfactory Neurogenesis , 2008, Neuron.
[42] Richard D. Smith,et al. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. , 2008, Journal of proteome research.
[43] Peter T. Nelson,et al. MicroRNAs (miRNAs) in Neurodegenerative Diseases , 2008, Brain pathology.
[44] J. Steitz,et al. Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.
[45] Margaret S. Ebert,et al. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.
[46] G. Hannon,et al. A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons , 2007, Science.
[47] S. Hébert,et al. miRNAs in Neurodegeneration , 2007, Science.
[48] Richard J Jackson,et al. MicroRNAs repress translation of m7Gppp-capped target mRNAs in vitro by inhibiting initiation and promoting deadenylation. , 2007, Genes & development.
[49] P. Greengard,et al. Cerebellar neurodegeneration in the absence of microRNAs , 2007, The Journal of experimental medicine.
[50] J. Keller,et al. RNA in Brain Disease: No Longer Just "The Messenger in the Middle" , 2007, Journal of neuropathology and experimental neurology.
[51] P S Whitton,et al. Inflammation as a causative factor in the aetiology of Parkinson's disease , 2007, British journal of pharmacology.
[52] W. Filipowicz,et al. Repression of protein synthesis by miRNAs: how many mechanisms? , 2007, Trends in cell biology.
[53] Shu Zheng,et al. What we know about ST13, a co-factor of heat shock protein, or a tumor suppressor? , 2007, Journal of Zhejiang University SCIENCE B.
[54] J. Growdon,et al. Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.
[55] M. Farrer,et al. The ups and downs of α‐synuclein mRNA expression , 2007 .
[56] L. Moran,et al. The medial and lateral substantia nigra in Parkinson’s disease: mRNA profiles associated with higher brain tissue vulnerability , 2007, Neurogenetics.
[57] L. Moran,et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra , 2007, Acta Neuropathologica.
[58] R. Levine,et al. Staufen- and FMRP-Containing Neuronal RNPs Are Structurally and Functionally Related to Somatic P Bodies , 2006, Neuron.
[59] B. Davidson,et al. RNA polymerase III transcribes human microRNAs , 2006, Nature Structural &Molecular Biology.
[60] Sonja W. Scholz,et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.
[61] R. Plasterk,et al. The diverse functions of microRNAs in animal development and disease. , 2006, Developmental cell.
[62] T. Klockgether,et al. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen , 2006, Experimental Neurology.
[63] N. Rajewsky. microRNA target predictions in animals , 2006, Nature Genetics.
[64] L. Moran,et al. Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease , 2006, Neurogenetics.
[65] T. Kaysser-Kranich,et al. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease , 2006, Neurobiology of Disease.
[66] Michael E. Greenberg,et al. A brain-specific microRNA regulates dendritic spine development , 2006, Nature.
[67] L. Moran,et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.
[68] Olga Varlamova,et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[69] Mariza de Andrade,et al. High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.
[70] E. Bézard,et al. Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease , 2005, Neurobiology of Disease.
[71] F. Dietrich,et al. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra , 2005, Movement disorders : official journal of the Movement Disorder Society.
[72] E. Tan,et al. Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[73] F. Middleton,et al. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[74] S. Mandel,et al. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin‐Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC‐70 , 2005, Annals of the New York Academy of Sciences.
[75] Ling Lin,et al. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. , 2005, Human molecular genetics.
[76] R. Jensen,et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. , 2005, Archives of neurology.
[77] K. Gunsalus,et al. Combinatorial microRNA target predictions , 2005, Nature Genetics.
[78] Lena Smirnova,et al. Regulation of miRNA expression during neural cell specification , 2005, The European journal of neuroscience.
[79] R. Russell,et al. Principles of MicroRNA–Target Recognition , 2005, PLoS biology.
[80] Axel T Brunger,et al. Structure and function of SNARE and SNARE-interacting proteins , 2005, Quarterly Reviews of Biophysics.
[81] C. Burge,et al. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.
[82] Anton J. Enright,et al. Human MicroRNA Targets , 2004, PLoS biology.
[83] Y. Suh,et al. α‐Synuclein induces apoptosis by altered expression in human peripheral lymphocytes in Parkinson’s disease , 2004 .
[84] S. Mandel,et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.
[85] Pasko Rakic,et al. Microarray analysis of microRNA expression in the developing mammalian brain , 2004, Genome Biology.
[86] Eden R Martin,et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. , 2004, American journal of human genetics.
[87] Thomas Tuschl,et al. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. , 2004, RNA.
[88] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[89] Konstantin Khrapko,et al. A microRNA array reveals extensive regulation of microRNAs during brain development. , 2003, RNA.
[90] Yoav Ben-Shlomo,et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.
[91] Kenneth S Kosik,et al. Neuronal RNA Granules A Link between RNA Localization and Stimulation-Dependent Translation , 2001, Neuron.
[92] J. Haines,et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. , 2001, JAMA.
[93] J. Joyce,et al. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[94] F. Hartl,et al. Hip, a novel cochaperone involved in the eukaryotic hsc70/hsp40 reaction cycle , 1995, Cell.
[95] M. Borg,et al. [Dopamine dysregulation syndrome in Parkinson's disease]. , 2008, Revue neurologique.
[96] R. Barker,et al. Neurotrophic factors as a therapeutic target for Parkinson's disease. , 2008, Expert opinion on therapeutic targets.
[97] M. Farrer,et al. The ups and downs of alpha-synuclein mRNA expression. , 2007, Movement disorders : official journal of the Movement Disorder Society.
[98] T. Kaufman,et al. Protein expression in a Drosophila model of Parkinson's disease. , 2007, Journal of proteome research.
[99] S. Cohen,et al. microRNA functions. , 2007, Annual review of cell and developmental biology.
[100] H. Clevers. Wnt/beta-catenin signaling in development and disease. , 2006, Cell.
[101] H. Braak,et al. Pathology associated with sporadic Parkinson's disease--where does it end? , 2006, Journal of neural transmission. Supplementum.
[102] J. Andersen,et al. Dopaminergic neurons. , 2005, The international journal of biochemistry & cell biology.
[103] Janette K Burgess,et al. Analysis of gene expression. , 2002, Methods in enzymology.
[104] C. Colosimo,et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease , 2001, Journal of Neural Transmission.
[105] H. Ichinose,et al. Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.